organon.com (OGN) Year-over-year earnings per share growth for the last twelve months

Brandmark of Organon Corp (OGN)

Biosimilar and women's health drug sales generate steady income, although fierce competition with market behemoths requires massive promotional expenditures. The quarterly EPS growth rate, verified via GURU.Markets, reflects a trend where -1.90 captures the current value of the indicator. This confirms the status of Organon & Co. (OGN) as a global ecosystem with a unique portfolio of reproductive brands that ensures patient loyalty.

Organon (OGN) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Organon Pharma (OGN)

- share price and expert price forecast:
Stock Price Organon|OGN - Average Forecast Price
- market capitalization details:
Market Value Organon Corp|OGN - Business Value
- book capitalization data:
Net Assets per Single Share Organon|OGN - Total Stockholders' Equity|Market Value to Book Value Ratio organon.com|OGN - Aggregate Asset Value
- debt and solvency information:
Total Debt to Capital Organon & Co.|OGN - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Organon & Co.|OGN - Company Aggregate Debts|Debt to Book Capitalization Ratio Organon Corp|OGN - Company Long-Term Indebtedness|Company Short-Term Debt Organon|Quick Liquidity organon.com
- earnings and market multiples details:
OGN - Company Profit|Future Profit Organon & Co.|OGN - Company Value to Net Income|Price to Future Earnings Ratio Organon Corp|OGN - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Organon Corp|OGN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Organon|OGN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months organon.com|OGN - Earnings per share growth rate in current year|Expected earnings per share growth for next year Organon & Co.
Initial company analysis:Organon & Co.
Flagship merchandise of Organon Pharma

This indicator reflects the dynamics of net income per share, stripping the financial result of subjective management assessments. The metric measures real capital generation efficiency by comparing current income with data from the previous quarter. By analyzing the quarterly EPS growth rate, an investor determines the business development stage. For Organon & Co. (OGN), this confirms the successful monetization of women's health medications. The growth of this indicator proves the viability of the strategy to launch affordable biosimilars.

Key competitors

DARE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months TherapeuticsMD (TXMD)|Year-over-year earnings per share growth for the last twelve months Palatin